MXPA01011660A - Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular. - Google Patents

Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.

Info

Publication number
MXPA01011660A
MXPA01011660A MXPA01011660A MXPA01011660A MXPA01011660A MX PA01011660 A MXPA01011660 A MX PA01011660A MX PA01011660 A MXPA01011660 A MX PA01011660A MX PA01011660 A MXPA01011660 A MX PA01011660A MX PA01011660 A MXPA01011660 A MX PA01011660A
Authority
MX
Mexico
Prior art keywords
sba
immune response
adjuvant
cellular immune
biocompatibility
Prior art date
Application number
MXPA01011660A
Other languages
English (en)
Inventor
Ller Rainer Helmut M
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of MXPA01011660A publication Critical patent/MXPA01011660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a un adyuvante optimizado en estabilidad y biocompatibilidad (SBA) para aumentar la respuesta humoral y celular en el caso de inyeccion junto con uno o mas antigenos. El adyuvante consiste de particulas a base de lipidos solidos o mezclas solidas de lipidos. Posibilidades de uso son la preparacion de vacunas mas eficientes y aceptables, inmunizacion de humanos y animales, pero tambien la obtencion de anticuerpos. Por medio de la seleccion del tamano de particula, la carga de la particula y las propiedades superficiales puede modularse de manera dirigida y ademas adecuarse especificamente a la especie. Al SBA pueden agregarse otros adyuvantes tambien, como por ejemplo adyuvantes moleculares como GMDP, con lo cual se aumenta de manera adicional la respuesta inmune celular. El SBA es mas efectivo, economicamente mas ventajoso y mas facil de manejar que los productos existentes y es bien tolerado in vivo.
MXPA01011660A 1999-05-20 2000-05-19 Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular. MXPA01011660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
MXPA01011660A true MXPA01011660A (es) 2004-04-05

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011660A MXPA01011660A (es) 1999-05-20 2000-05-19 Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.

Country Status (11)

Country Link
EP (1) EP1183045A2 (es)
JP (1) JP2003500365A (es)
KR (1) KR20020012221A (es)
AU (2) AU5214200A (es)
BR (1) BR0010823A (es)
CA (1) CA2373239A1 (es)
DE (1) DE10024788A1 (es)
MX (1) MXPA01011660A (es)
TR (1) TR200103333T2 (es)
WO (2) WO2000071154A2 (es)
ZA (1) ZA200109147B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011660A (es) * 1999-05-20 2004-04-05 Pharmasol Gmbh Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
JP2007509164A (ja) * 2003-10-23 2007-04-12 カイロン コーポレイション 安定化組成物
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
AR072114A1 (es) 2008-06-13 2010-08-04 Mannkind Corp Un inhalador de polvo seco y sistema para suministro de farmacos
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
WO2013165909A1 (en) 2012-04-30 2013-11-07 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3386540A1 (en) * 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
EP1100464A1 (en) * 1998-07-31 2001-05-23 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
MXPA01011660A (es) * 1999-05-20 2004-04-05 Pharmasol Gmbh Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.

Also Published As

Publication number Publication date
DE10024788A1 (de) 2000-11-23
WO2000071154A3 (de) 2001-06-28
WO2000071077A2 (en) 2000-11-30
JP2003500365A (ja) 2003-01-07
KR20020012221A (ko) 2002-02-15
AU5809100A (en) 2000-12-12
EP1183045A2 (de) 2002-03-06
CA2373239A1 (en) 2000-11-30
ZA200109147B (en) 2002-05-08
TR200103333T2 (tr) 2002-04-22
WO2000071154A2 (de) 2000-11-30
BR0010823A (pt) 2002-03-05
AU5214200A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
MXPA01011660A (es) Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.
HK1121382A1 (en) Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines
EP1333858B8 (en) Vaccines with enhanced immune response and methods for their preparation
AU3847801A (en) Proteosome influenza vaccine
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO1999041369A3 (en) Genetic vaccine vector engineering
MY125202A (en) Vaccine
WO2002034205A3 (en) Using heat shock proteins to increase immune response
PL351893A1 (en) Vaccines
WO2005037190A3 (en) Multiplex vaccines
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
WO2003039595A3 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
NO331017B1 (no) Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.
CA2272338A1 (en) Immunization of infants
WO2005007673A3 (en) Immunogenic peptides
WO2002009752A3 (en) Immunological adjuvant compounds
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
WO2005012538A3 (en) Accelerated vaccination
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
AU2003229435A8 (en) Pathogen vaccines and methods for using the same
AU2003296592A8 (en) Antigen-complexes
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form